SCIENCE THROUGH NETWORKING

WHAT ARE THE ATMPS

 

The definition of advanced therapies (ATMPs) includes a heterogeneous series of medicinal products. The European Medicines Agency (EMA) defines as advanced therapies:

  • Gene therapies: medicinal products containing recombinant nucleic acid as active substance thus to regulate, repair, replace, add or delete a genetic sequence or medicinal products whose therapeutic / prophylactic / diagnostic effect relates directly to the recombinant nucleic acid sequence or to its product of genetic expression.
  • Somatic cell therapy medicinal products: cells substantially manipulated to acquire specific biological properties or cells/ tissues not intended to be used for the same essential functions in the body.
  • Tissue engineered products:  cells or tissues grown on 3D scaffold so they can be used to repair, regenerate or replace human tissue. 

WHO WE ARE

 

ATMP FORUM is a virtual agorà where all stakeholders can directly interact and discuss on ATMPs clinical, economical and organizational advances and issues. An efficient and sustainable access to advanced therapy as well as the promotion of public-private partnership are a win win goal and priority for all the actors involved and patients first. 

Our aim is to improve Italian experience and expertise to make our Country a leader of ATMPs scenario and we are working for this. 


SCIENTIFIC BOARD

 

Pier Luigi Canonico (Chair)
Professor of Pharmacology, Universita’ del Piemonte Orientale (UPO), Novara 
Claudio Jommi (Chair)
Scientific Director of the Pharmaceutical Observatory at Cergas SDA Bocconi University, Milan and Associate Professor of Management at the Department of Pharmaceutical Sciences, Università del Piemonte Orientale (UPO), Novara
Elena Paola Lanati
ATMP Forum Director, Milan
Alessandro Aiuti
Professor of Pediatrics, Università Vita Salute San Raffaele; Director of Immuno-oncological Pediatric Unit, San Raffaele Hospital; Vice-Director of San Raffaele Telethon Institute for Gene Therapy, Milan
Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy
Giorgio Calesella
Lawyer Studio Legale Calesella, Milan
Rachele Ciccocioppo
Associate Professor in Gastroenterology, Università degli Studi di Verona
Cecilia Maini
Life Sciences Regional Technology Platform Coordinator Aster, Bologna
Enrica Morra
Scientific Coordinator of Region Haematological Network (REL), Milan; President of “Fondazione Malattie del Sangue Onlus”; Hematologist at ASST Grande Ospedale Metropolitano Niguarda, Milan
Maria Luisa Nolli
Member of the board of Assobiotec and EUROPABIO, Rome
Marcello Pani
Director of “Hospital pharmacy” Unit - Policlinico Universitario Agostino Gemelli IRCCS Roma; Member of Executive Board of Italian Society of Hospital Pharmacy (SIFO)
Concetta Quintarelli
Director of Lab of Tumours Gene therapy, Pediatric Hospital Bambin Gesù (Rome); Researcher at Department of Clinical Medicine and Surgery, University of Naples Federico II
Anna Paola Salvetti
Researcher, Dept. of Biomedical and Clinical Sciences “Luigi Sacco”, Università degli Studi di Milano
Andrea Sodi
Director of the Regional Reference Centre for Hereditary Retinal Degeneration, Dept. Ophtalmology, Careggi Hospital, Florence; Secretary of Italian Society of Genetic Ophtalmlogy (SIOG)

With the unconditional support of

 

Nuovo BMS CELGENE
galta ris
Janssen

 

novartis logo pos cmyk c
Roche cmyk
Takeda Symbol Color pos

We use cookies, just to track visits to our website, we store no personal details